Epi One

Epi One Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Epi One, Biotechnology company, 760 Parkside Avenue, Brooklyn, NY.

We are on a mission to build a revolutionary cancer diagnosis platform to solve the challenge of early cancer prognosis and detection, as well as prediction of post-diagnosis cancer drug response.

12/04/2024

🚨 Final hours of our funding round! It's now or never to join us at this valuation.

Why I invested & became CEO of Epi One: We're revolutionizing early cancer detection - a mission that's deeply personal to me and could help millions.

Our edge:
-DNA biomarker tech aiming for faster, more precise detection
-Affordable tests making early screening accessible
-Impressive accuracy
-Built for scale & mass adoption
-Solid backing: $3.1M angel funding + expert team

Already blown away by our investor community - thank you! 🙏

2025 will be huge - we can't wait to share updates on our journey to transform healthcare.

Learn more: https://bit.ly/4e7WVrA

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Today is the last day of our investment round. We want to address a question that often arises in blood-based cancer det...
12/03/2024

Today is the last day of our investment round. We want to address a question that often arises in blood-based cancer detection technologies: "How is this different from Theranos?"

Epi One's Commitment to Transparency and Scientific Rigor:

✅ Peer-Reviewed Research: Our technology is based on published, peer-reviewed scientific work. We welcome scrutiny and validation from the scientific community.

✅ Realistic Claims: We're clear about our pre-revenue status and the ongoing development of our technology. We don't promise what we can't deliver.

✅ Experienced Leadership: Our team includes seasoned scientists and biotech professionals with track records in cancer research and diagnostics.

✅ Open Collaboration: We actively collaborate with academic institutions and industry partners, sharing data and methodologies.

✅ Regulatory Compliance: We follow established regulatory pathways for diagnostic test development and approval.

Our progress to date includes raising over $4.7 million from more than 360 investors, conducting ongoing clinical validations, and establishing a clear roadmap for regulatory approvals.

Remember, as a pre-revenue company, investment carries risks. We're transparent about our stage and the work ahead.

With one day left, we invite you to be part of our mission to transform early cancer detection through rigorous science and ethical innovation.

Learn more: https://bit.ly/4e7WVrA

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

12/03/2024

🎥 Miss our final investor webinar? Watch the replay.

CEO Michael Marquardt and Co-Founder Dr. Sophia Fang discuss:
✅ Our DNA-based cancer detection technology
✅ $75B+ annual US market for cancer testing
✅ Path to commercialization
✅ Global expansion vision

Plus: Why Dr. Fang believes our biomarker accuracy sets us apart in cancer diagnostics.

Campaign closing soon - don't miss your chance to learn more.
Watch now: https://bit.ly/3CSJeit



This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

12/02/2024

🎯 Milestone reached: 375+ investors have joined Epi One's mission to enhance early cancer detection through DNA-based testing!

With less than one week left in our offering & $4.6M+ raised, here's why investors believe in us:
📈 Cancer rates rising 1-2% yearly in young adults
🔬 Targeting $70B diagnostics market by 2032
⏰ Early detection remains essential to improving outcomes

Learn more & join us: https://bit.ly/4e7WVrA
Note: Investment involves risks. See offering details.

⏰ Last call to join CEO Michael Marquardt and Co-Founder/Chief Scientific Officer Dr. Sophia Fang tomorrow to discuss Ep...
11/26/2024

⏰ Last call to join CEO Michael Marquardt and Co-Founder/Chief Scientific Officer Dr. Sophia Fang tomorrow to discuss Epi One's early cancer detection technology before our StartEngine campaign closes next week.

Key topics:
✅ DNA-based biomarker technology
✅ Development timeline
✅ $70B market opportunity

Register now👇
https://bit.ly/4fHnXqF

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

11/22/2024

🧬 Groundbreaking cancer detection update! Catch the highlights from our webinar with CEO Michael Marquardt & lead investor Daniel Etra:
📊 93-96% accuracy rates
🔬 Multi-cancer validation
📋 First patent secured
🏥 CLIA lab launching 2025
⚡️ Results in hours vs weeks

🎥 Watch the full replay: https://bit.ly/40UaKGn

⏰ Final webinar: Nov 26 @ 4:30 PM ET
StartEngine campaign ends very soon!

Join our mission to revolutionize early cancer detection!👇
https://bit.ly/4e7WVrA



This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Magic doesn't just happen—it's created through dedication, precision, and countless hours of focused work. Every pipette...
11/21/2024

Magic doesn't just happen—it's created through dedication, precision, and countless hours of focused work.

Every pipette, every carefully measured sample, and every meticulously run test brings us one step closer to our goal of radically improving early cancer detection.
To all our incredible lab staff: your passion fuels our mission. Your attention to detail ensures our science is sound. Your perseverance in the face of challenges inspires us all.

Today, we celebrate the quiet, determined work that happens behind these lab doors. It's here, in these moments of intense focus and careful ex*****on, that the future of cancer diagnostics is being shaped.

Thank you to our amazing lab team. Your work may happen behind the scenes, but its impact will be felt far beyond these walls.

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

11/20/2024

Some journeys begin with loss but lead to hope. After I lost my first wife to late-stage cancer, I committed myself to doing everything possible to prevent other people from having to go through a devastating loss like I did. Today, I'm leading Epi One to revolutionize early detection.

Our mission: Make cancer screening accessible and affordable for everyone.
With two weeks left in our investment round, we're closer than ever to turning this vision into reality. Every investment brings us one step closer to a world where 'too late' is no longer in the cancer vocabulary.

Join us. Invest in Epi One. Invest in hope.👇
https://bit.ly/4e7WVrA

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

11/19/2024

Final Investment Webinar: November 26th at 4:30pm ET! Join Epi One CEO and Chief Scientist for our last StartEngine investor webinar.

✅ Live company overview
✅ Latest progress updates
✅ Open Q&A session

Register now👇
https://bit.ly/4fwgV87

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Imagine waiting days, even weeks, for a potentially life-changing diagnosis. The uncertainty is overwhelming. At Epi One...
11/19/2024

Imagine waiting days, even weeks, for a potentially life-changing diagnosis. The uncertainty is overwhelming.

At Epi One, we believe no one should have to endure that wait. With the U.S. cancer diagnostics market set to reach $70 billion by 2032, we're bringing faster, more affordable solutions to the forefront.

Our advanced platform aims to provide answers when they’re needed most. Ready to support a future where timely detection can change lives?

Learn how you can join us on StartEngine.👇
https://www.startengine.com/offering/epi-one

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

This unassuming machine packs a powerful punch in the fight against cancer. PCR (Polymerase Chain Reaction) technology i...
11/15/2024

This unassuming machine packs a powerful punch in the fight against cancer. PCR (Polymerase Chain Reaction) technology is the backbone of Epi One's innovative approach to early cancer detection.

PCR is a laboratory technique that makes millions of copies of a specific DNA segment, allowing scientists to study and analyze genetic material more easily.
By harnessing the capabilities of PCR, we're working towards a future where affordable, mass-produced cancer screening becomes a reality.

Our goal? To catch cancer early, when it's most treatable, and make these tests accessible to everyone.
While we're still in development, this little powerhouse represents big hopes for revolutionizing cancer diagnostics.

This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

11/15/2024

The numbers are sobering: Cancer rates in young adults are rising 1-2% each year, with more diagnoses happening before age 50. Epi One is working toward solving this problem with its DNA-based testing platform.

Our StartEngine equity crowdfunding campaign has reached the $1.5 million mark, moving us closer to our goal of advancing early cancer detection technology.

With less than a month remaining in our offering, this is an opportunity to join over 300 investors who believe in our mission to support early, accurate cancer diagnosis and treatment.

About Epi One:
✅ Developing a DNA-based testing platform for improved early cancer detection.
✅ Targeting the broader U.S. cancer diagnostics market.
✅ Backed by $3.1M in angel funding, patented and third-party validated.

Please remember that investing in early-stage companies carries substantial risks, including the risk of complete loss of investment. We encourage you to review our offering details and risk disclosures here: https://bit.ly/4e7WVrA

Address

760 Parkside Avenue
Brooklyn, NY
11226

Telephone

+17185698789

Website

Alerts

Be the first to know and let us send you an email when Epi One posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category